INNATE PHARMA (EPA:IPH) Number of shares and voting rights and cash situation of INNATE PHARMA as at December 31, 2009

Transparency directive : regulatory news

08/01/2010 18:15

PRESS RELEASE

NUMBER OF SHARES AND VOTING RIGHTS AND CASH SITUATION OF INNATE PHARMA AS AT
DECEMBER 31, 2009

Marseilles, France, January 8, 2010

Following the capital increase reserved to categories of investors executed in
December 2009 and pursuant to the article L. 233-8 II of the French "Code de
Commerce" and the article 223-16 of the French stock-market authorities
(Autorité des Marchés Financiers, or "AMF") charter, Innate Pharma SA
(Euronext Paris: FR0010331421 - IPH) updates its total number of shares
outstanding as well as its voting rights as at December 31, 2009:

     Total number of shares outstanding:    36 636 794
     Voting rights:                         36 636 794

Following the capital increase, cash, cash equivalents and current financial
instruments amounted to 49.2 million euros as at December 31, 2009.

Innate Pharma will announce its turnover for 2009 on February 5, 2010.

Following the recent announcement of its financial calendar for 2010, the
Company amends the date of its General Shareholders Meeting which will
eventually take place in Marseilles on May 25, 2010.

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biopharmaceutical company developing
first-in-class immunotherapy drugs for cancer and other severe diseases. The
Company was incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006.
The Company has two drug candidates currently in Phase II clinical trials. Two
of its preclinical programs are out-licensed to Novo Nordisk A/S.

Innate Pharma is based in Marseilles, France, and had 80 employees as at
December 31, 2009. Learn more about Innate-Pharma at www.innate-pharma.com

Practical Information about Innate Pharma shares:

ISIN code         FR0010331421
Ticker code       IPH

Disclaimer:

This press release contains information on the markets on which the Company
operates and forward-looking statements. Although the Company believes this
information and these expectations are based on reasonable assumptions, this
information and these forward-looking statements are subject to numerous risks
and uncertainties, which could cause actual results to differ materially from
those anticipated. For a discussion of risks and uncertainties which could cause
the Company's actual results, financial condition, performance or achievements
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the Document de Reference
prospectus filed with the AMF, which is available on the AMF website
(www.amf-france.org) or on Innate Pharma's website (www.innatepharma.com).

.

For additional information, please contact:

Innate Pharma                  Alize Public Relations
Laure-Hélène Mercier,          Caroline Carmagnol
Director, Investor Relations   Phone: +33 (0)1 42 68 86 40
Phone: +33 (0)4 30 30 30 87    Mobile: +33 (0)6 64 18 99 59
investors@innate-pharma.fr     caroline@alizerp.com

100108 nb shares and cash situation as at 091231

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Number of shares and voting rights and cash situation of INNATE PHARMA as at December 31, 2009

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories